Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

Rhea-AI Summary

Precipio (NASDAQ: PRPO) will present a joint study with Memorial Sloan Kettering at the 2025 ASH meeting showing results from 895 patient samples evaluating Precipio’s BCR::ABL1 assay. The study reports superior assay performance and concordance with two leading platforms, plus improvements in patient care and laboratory workflows. The poster presentation and results discussion are scheduled for December 8, 2025, 6:00–8:00 PM at OCCC West Halls B3-B4.

Key Figures

Patient samples 895 samples Study evaluating Precipio’s BCR::ABL1 assay

Q3-2025 revenue $6.8M Quarter ended Q3-2025, up 30% YoY and 20% QoQ

Q2-2025 revenue $5.7M Quarter ended Q2-2025, 27% YoY and 15% QoQ growth

Q3-2025 Adjusted EBITDA $469K Positive vs. $100K in Q3-2024

Q3-2025 operating cash flow $285K Before Change Healthcare transactions, vs. Q2-2025 burn of $148K

Q3-2025 net sales $6,767K As reported in the 10-Q filing for Q3 2025

Q3-2025 net loss $79K Improved from $626K a year ago

Quarter-end cash $2,305K Cash at Q3 2025 quarter-end per 10-Q

Market Reality Check

$24.95 Last Close

Volume Volume 6,720 is below the 20-day average of 14,600 ahead of this ASH update. low

Technical Shares at $24.95 are trading above the 200-day MA of $13.38 and 12.46% below the 52-week high.

Peers on Argus

Peers showed mixed moves: NOTV +1.28%, BIAF +8.18%, ISPC +4.73%, while PRPH and ADVB were modestly negative. With PRPO down 1.77%, action appears stock-specific rather than a coordinated sector swing.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 14	Earnings release	Positive	+8.8%	Q3‑2025 revenues rose to <b>$6.8M</b> with stronger EBITDA and cash flow.
Nov 04	Shareholder call update	Neutral	+2.9%	Scheduled Q3‑2025 shareholder update call and Q&A access details.
Sep 02	Capital tool change	Positive	-0.7%	Termination of ATM program following improved cash flow and cash balance.
Aug 13	Earnings release	Positive	+2.9%	Q2‑2025 revenue growth to <b>$5.7M</b> with better margins and cash use.
Jul 31	Shareholder call update	Neutral	+1.4%	Announcement of Q2‑2025 shareholder update conference call logistics.

Pattern Detected

Recent fundamental and corporate updates have mostly seen modest positive price alignment, with only the ATM termination drawing a small negative reaction.

Recent Company History

This announcement adds a clinical-utility angle to a year dominated by financial improvement and capital-structure moves. Q2 and Q3‑2025 results showed revenue growth to $5.7M and $6.8M, expanding gross margins and improving EBITDA and cash flow. The company later terminated its ATM, citing stronger finances. Shareholder update calls on Aug 14 and Nov 17 kept investors engaged. Against that backdrop, showcasing an 895‑sample BCR::ABL1 study at ASH underscores ongoing product and clinical validation efforts.

Market Pulse Summary

This announcement spotlights clinical validation of Precipio’s BCR::ABL1 assay using 895 patient samples, with reported superiority versus other platforms and workflow improvements. It complements earlier Q2 and Q3‑2025 updates that showed stronger revenues and better cash metrics. At the same time, the latest 10‑Q disclosed “substantial doubt” about going‑concern status, so investors may watch how assay adoption, cash levels of $2.3M, and future filings evolve after the ASH presentation.

Jargon Translator

atm offering

An at-the-market offering is a way for a company to sell new shares of its stock directly into the stock market over time, usually through a designated sales program. This approach allows the company to raise funds gradually as needed, similar to adding small amounts of fuel to a car rather than filling the tank all at once. For investors, it can influence the company's stock price and provide insights into its financing plans.

beneficial ownership

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Rule 10b5-1 trading plan

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

schedule 13g

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. Not financial advice.

Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care

NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio’s BCR::ABL1 assay.

The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows.

Poster presentation of the study abstract, and results discussion are scheduled for Monday December 8^th from 6:00-8:00pm at the OCCC room in West Halls B3-B4 at the ASH Meeting in Orlando, Florida.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.

Availability of Other Information About Precipio

For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Inquiries:

investors@precipiodx.com

+1-203-787-7888 Ext. 523

FAQ

What did Precipio announce about the BCR::ABL1 assay at ASH 2025 (PRPO)?

Precipio announced a joint study with Memorial Sloan Kettering showing superior performance of its BCR::ABL1 assay across 895 patient samples and concordance with two other platforms.

When and where will Precipio (PRPO) present the BCR::ABL1 study at ASH 2025?

The poster and results discussion are scheduled for December 8, 2025, 6:00–8:00 PM at OCCC West Halls B3-B4 in Orlando, Florida.

How many patient samples were included in the Precipio BCR::ABL1 ASH 2025 study (PRPO)?

The study evaluated 895 patient samples.

Does the Precipio ASH 2025 study show clinical impact for patients (PRPO)?

Yes; the study reports clear, positive impacts on patient care alongside laboratory workflow improvements.

Did the Precipio BCR::ABL1 study compare results to other platforms (PRPO)?

Yes; the study shows concordance with two other leading platforms while reporting superior assay performance.

Where can investors view the Precipio ASH 2025 poster presentation (PRPO)?

The poster will be displayed at the ASH meeting in Orlando (OCCC West Halls B3-B4) on December 8, 2025, 6:00–8:00 PM.